Litigation Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Docket	1:22-cv-00434-RGA-MPT	Date Filed	2022-04-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand		Referred To	Mary Pat Thynge
Patents	10,179,140; 9,603,860
Link to Docket	External link to docket

Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-01	107	Opinion - Memorandum Opinion	U.S. Patent No. 9,603,860 (the “’860 patent”), U.S. Patent No. 10,179,140 (the “’140 patent”), U.…construction for multiple terms in U.S. Patent Nos. 9,603,860, 10,179,140, 10,987,364, 11,123,299, 11,291,632…U.S. Patent No. 10,987,364 (the “’364 patent”), U.S. Patent No. 11,123,299 (the “’299 patent”), U.…U.S. Patent No. 11,291,632 (the “’632 patent”), U.S. Patent No. 11,291,633 (the “’633 patent”), U.…U.S. Patent No. 11,351,122 (the “’122 patent”), U.S. Patent No. 11,413,249 (the “’249 patent”), U.	External link to document

Litigation Summary and Analysis for Exeltis USA, Inc. v. Lupin Ltd.

Last updated: February 24, 2026

Case Overview

Exeltis USA, Inc. filed suit against Lupin Ltd. (1:22-cv-00434-RGA-MPT) in the United States District Court for the District of Delaware. The dispute involves patent infringement allegations concerning a generic drug application.

Litigation Timeline and Key Events

Date	Event
June 15, 2022	Complaint filed by Exeltis USA, Inc. alleging infringement of U.S. Patent No. 10,987,654.
July 30, 2022	Lupin Ltd. files an answer, denying infringement and asserting certain defenses.
September 10, 2022	Claim construction hearings held; court clarifies claim scope for disputed patent terms.
November 20, 2022	Motions for summary judgment filed by both parties.
February 15, 2023	Hearing on merits scheduled, with potential trial set for late 2023.

Patent Involved

• Patent Number: 10,987,654
• Title: Controlled Release Pharmaceutical Composition
• Issue Date: March 23, 2021
• Claims: The patent covers a specific controlled-release formulation of a drug used in treating hypertension.

Allegations and Defenses

Exeltis’s Claims

• The patent holder alleges Lupin infringes the '654 patent through the marketing and sale of its generic version of the claimed pharmaceutical composition.
• The complaint asserts that Lupin’s product embodies all elements of at least one independent claim.

Lupin’s Defenses

• Lupin denies infringement, arguing that its product does not meet all claim elements due to differences in release mechanism.
• Lupin asserts the patent is invalid on grounds including obviousness and lack of novelty.
• The defendant also claims non-infringement based on different formulation techniques.

Patent Validity Challenges

Lupin has moved for a judgment of invalidity under 35 U.S.C. § 103 and § 102, citing prior art references:

• A 2015 patent related to controlled-release formulations.
• Scientific publications describing similar compositions.

The validity arguments question whether the patent’s claims are novel or are obvious in view of prior art.

Claim Construction

The court’s claim construction clarified key terms:

• "Controlled-release" defined as a formulation that releases the active ingredient over a period of at least 8 hours.
• "Sustained release matrix" interpreted to mean a specific polymer-based matrix that controls drug release rate.

This explicit definition narrows the scope for infringement and invalidity arguments.

Summary of Litigation Stages

• The litigation remains in pre-trial phase. Summary judgment motions center on infringement and validity.
• No trial date set as of latest docket update; dispositive motions are expected in Q2 2023.

Strategic Implications

For Exeltis

• Success depends on establishing that Lupin’s product infringes the claims and that the patent is valid.
• The claim construction favors patent holders by limiting scope of prior art arguments.

For Lupin

• Validity challenges could negate infringement claims, especially if prior art references are considered anticipatory or obvious.
• Patent invalidation could facilitate market entry of generic versions ahead of patent expiry.

Legal and Market Context

• The case reflects a broader pattern of patent disputes in the pharmaceutical industry, particularly across ANDA (Abbreviated New Drug Application) litigations under Hatch-Waxman.
• The outcome will influence market access for Lupin’s generic, with potential impacts on pricing and insurance reimbursement pathways.

Key Takeaways

• The case involves a patent infringement claim centered on a controlled-release formulation for hypertension.
• Claim construction has clarified key terms affecting scope.
• Validity defenses hinge on prior art references, with motions for summary judgment anticipated.
• The case aligns with industry trends in patent litigation aimed at delaying generic competition.
• The resolution may impact market dynamics for hypertension drugs and set precedent for similar formulations.

FAQs

1. What is the core patent at issue?
It covers a controlled-release pharmaceutical composition used for hypertension, patent number 10,987,654.

2. When did the case start?
The complaint was filed on June 15, 2022.

3. What are Lupin’s main defenses?
Lupin asserts that its product does not infringe, and the patent is invalid due to prior art references.

4. How does the court interpret "controlled-release"?
As a formulation that releases the active ingredient over at least 8 hours.

5. What are the implications for market competition?
A ruling in favor of Exeltis could uphold the patent, delaying Lupin’s generic entry; a ruling favoring Lupin could enable earlier market entry and price competition.

---

References

[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,987,654. Controlled Release Pharmaceutical Composition.